Jeffrey Jones
Family · Belpre, OHNPI 1598352288
Payments from drug & device makers
Across 194 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$658
- Novo Nordisk$433
- Boehringer Ingelheim$276
- Corcept Therapeutics$256
- Insulet Corporation$212
- Dexcom, Inc.$197
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,26897%
- Education$903%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 41 | $658 |
| Novo Nordisk | 28 | $433 |
| Boehringer Ingelheim | 14 | $276 |
| Corcept Therapeutics | 14 | $256 |
| Insulet Corporation | 10 | $212 |
| Dexcom, Inc. | 12 | $197 |
| Sanofi-aventis U.S. LLC | 10 | $185 |
| Alkermes, Inc. | 7 | $120 |
| AstraZeneca(2 entities) | 7 | $112 |
| Amgen | 7 | $108 |
| Averitas Pharma Inc. | 5 | $105 |
| Xeris Pharmaceuticals, Inc. | 5 | $93 |
| BETA Bionics, Inc. | 7 | $77 |
| OPKO Pharmaceuticals, LLC | 4 | $76 |
| Bayer | 4 | $66 |
| Tandem Diabetes Care, Inc. | 3 | $58 |
| Novartis | 3 | $51 |
| Cequr Corporation | 1 | $51 |
| Medtronic | 2 | $44 |
| Mannkind Corporation | 2 | $36 |
| AbbVie | 2 | $30 |
| Radius Health, Inc. | 1 | $25 |
| Chiesi USA, Inc. | 1 | $20 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Amryt Pharma Holdings Ltd | 1 | $18 |
| RGH Enterprises LLC | 1 | $15 |
How this compares
$3,358 in reported general payments places this provider in the 90th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 268 | $477,484 |
| MounjaroTirzepatide | 270 | $373,316 |
| JardianceEmpagliflozin | 265 | $288,183 |
| JanuviaSitagliptin Phosphate | 70 | $91,351 |
| TrulicityDulaglutide | 65 | $78,432 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $70,012 |
| TradjentaLinagliptin | 46 | $59,322 |
| FarxigaDapagliflozin Propanediol | 44 | $58,721 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 73 | $53,711 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $48,642 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 268 | $45,991 |
| Tresiba Flextouch U-100Insulin Degludec | 47 | $37,353 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 22 | $32,299 |
| RybelsusSemaglutide | 14 | $32,228 |
| Humalog Kwikpen U-100Insulin Lispro | 66 | $30,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $433 | $517,120309 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $658 | $465,500402 claims |
| Boehringer IngelheimJardiance, Tradjenta | $276 | $347,505311 claims |
| AstraZenecaFarxiga | $112 | $58,72144 claims |
| AmgenEvenity (2 Syringes) | $108 | $28,18812 claims |
| AbbVieSynthroid | $30 | $3,38753 claims |
| Sanofi-aventis U.S. LLCLantus | $185 | $3,10414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,812 family providers in Ohio.
Other family in Belpre
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
- George KnightCincinnati$130K
- Jillian HuntCincinnati$116K
- Florence StewartNew Albany$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.